Cardiff Oncology (CRDF) 10-Q 5 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document and Entity Information
Entity Registrant Name	Trovagene, Inc.
Entity Central Index Key	1213037
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		24,455,107
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$43,995,642	$27,293,798
Accounts receivable	59,391	56,694
Prepaid expenses and other assets	418,040	369,259
Total current assets	44,473,073	27,719,751
Property and equipment, net	1,022,534	840,387
Other assets	336,708	336,708
Total Assets	45,832,315	28,896,846
Current liabilities:
Accounts payable	484,709	747,799
Accrued expenses	1,755,803	1,841,808
Current portion of long-term debt	3,064,734	1,898,548
Total current liabilities	5,305,246	4,488,155
Long-term debt, less current portion	12,011,645	13,053,117
Derivative financial instruments	4,952,749	3,006,021
Total Liabilities	22,269,640	20,547,293
Commitments and contingencies (Note 8)
Stockholders' equity
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 60,600 shares outstanding at March 31, 2015 and December 31, 2014: designated as Series A Convertible Preferred Stock with liquidation preference of $606,000 at March 31, 2015 and December 31, 2014	60	60
Common stock, $0.0001 par value, 150,000,000 shares authorized; 24,307,291 and 18,902,782 shares issued and outstanding at March 31, 2015 and December 31,2014, respectvely	2,431	1,891
Additional paid-in capital	112,132,535	89,739,511
Accumulated deficit	-88,572,351	-81,391,909
Total stockholders' equity	23,562,675	8,349,553
Total liabilities and stockholders' equity	$45,832,315	$28,896,846

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares outstanding	60,600	60,600
Series A Convertible Preferred Stock, liquidation preference (in dollars)	$606,000	$606,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	24,307,291	18,902,783
Common stock, shares outstanding	24,307,291	18,902,782

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Royalty income	$124,804	$110,953
Diagnostic services revenue	2,166
Total revenues	126,970	110,953
Costs and expenses:
Cost of revenue	176,425
Research and development	2,197,659	1,442,521
Selling and marketing	794,653	569,590
General and administrative	1,805,985	1,358,480
Total operating expenses	4,974,722	3,370,591
Loss from operations	-4,847,752	-3,259,638
Interest income	6,369	2,391
Interest expense	-389,838	-9,496
Gain on disposal of equipment	3,568	44,101
(Loss) gain from change in fair value of derivative instruments-warrants	-1,946,728	32,846
Net loss and comprehensive loss	-7,174,381	-3,189,796
Preferred stock dividend	-6,060	-9,210
Net loss and comprehensive loss attributable to common stockholders	($7,180,441)	($3,199,006)
Net loss per common share - basic	($0.33)	($0.17)
Net loss per common share - diluted	($0.33)	($0.17)
Weighted average shares outstanding - basic	21,817,710	18,902,782
Weighted average shares outstanding - diluted	21,817,710	18,902,782

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating activities:
Net loss	($7,174,381)	($3,189,796)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on disposal of fixed assets	-3,568	-44,101
Depreciation and amortization	68,519	53,528
Stock based compensation expense	711,741	559,773
Amortization of debt costs	124,713
Accretion of discount on debt	28,486
Loss (gain) from the change in fair value of financial instruments - warrants	1,946,728	-32,846
Changes in operating assets and liabilities:
Increase in accounts receivable	-2,697	-50,309
Increase in prepaid expenses	-48,781	-109,399
(Decrease) increase in accounts payable and accrued expenses	-383,642	14,479
Net cash used in operating activities	-4,732,882	-2,798,671
Investing activities:
Capital expenditures, net of proceeds from disposals	-247,097	-118,507
Net cash used in investing activities	-247,097	-118,507
Financing activities:
Proceeds of sale of common stock, net of expenses	21,445,785
Proceeds from exercise of options	236,038
Repayments of debt under equipment line of credit		-48,637
Net cash provided by (used in) financing activities	21,681,823	-48,637
Net change in cash and equivalents	16,701,844	-2,965,815
Cash and cash equivalents-Beginning of period	27,293,798	25,836,937
Cash and cash equivalents-End of period	43,995,642
Supplementary disclosure of cash flow activity:
Cash paid for taxes	800	2,400
Cash paid for interest	265,125	6,601
Supplemental disclosure of non-cash investing and financing activities:
Preferred stock dividends accrued	$6,060	$9,210

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization and Basis of Presentation
Organization and Basis of Presentation
	1. Organization and Basis of Presentation
	Business Organization and Overview
	On April 26, 2002, the Company was incorporated in the State of Florida. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was in business to develop and commercialize urine-based molecular diagnostics technology. In 2007, the Company changed its fiscal year end from January 31 to December 31. In January 2010, the Company re-domesticated its state of incorporation from Florida to Delaware and the name was changed to Trovagene, Inc. In June 2012, the Company’s common stock was listed on The NASDAQ Capital Market under the ticker symbol TROV.
	Trovagene, Inc. (“Trovagene” or the “Company”) is a molecular diagnostic company that focuses on the development and commercialization of a proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. Trovagene’s primary internal focus is to leverage its novel urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while the Company’s external focus includes entering into collaborations to develop the Company’s technology in areas such as infectious disease, transplant medicine, and prenatal genetics. The Company’s goal is to improve treatment outcomes for cancer patients using its proprietary technology to detect and quantitatively monitor cell-free DNA in urine. Circulating tumor DNA (“ctDNA”) is a subtype of cell-free DNA, and represents the mutant cell free DNA that we use to detect and monitor cancer.
	Basis of Presentation
	The accompanying consolidated financial statements of Trovagene, which include its wholly owned subsidiaries Xenomics, Inc., a California corporation, Xenomics Europa Ltd, (an inactive subsidiary formed in the United Kingdom and liquidated) and Etherogen, Inc., a Delaware corporation, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).  All intercompany balances and transactions have been eliminated.
	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The unaudited interim condensed consolidated financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited interim condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2014 included in the Company’s annual report on Form 10-K filed with the SEC on March 12, 2015.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
	2. Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
	Revenue Recognition
	Revenue is recognized when persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.
	Milestone, Royalty and License Revenues
	The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners.   These agreements may involve multiple elements such as license fees, royalties and milestone payments.  Revenue is recognized when the criteria described above have been met as well as the following:
		·		Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured.
		·		Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured.
		·		Milestone payments are recognized when both the milestone is achieved and the related payment is received.
	Diagnostic Service Revenues
	Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, bill third-party payors for testing.
	Diagnostic services revenue is recognized when the criteria described above has been met as well as upon cash collection until the Company can reliably estimate the amount that will be ultimately collected for our LDTs, at which time the Company will recognize diagnostic services revenues on an accrual basis.
	Derivative Financial Instruments—Warrants
	The Company has issued common stock warrants in connection with the execution of certain equity financings.  Such warrants are classified as derivative liabilities under the provisions of FASB ASC 815 Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period.  Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity.  Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.”
	The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of Trovagene’s common share price, remaining life of the warrant, and risk-free interest rates at each period end.  The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per ASC 820, Fair Value Measurements.  At March 31, 2015, and December 31, 2014, the fair value of these warrants was $4,952,749 and $3,006,021, respectively, and were included in the derivative financial instruments liability on the balance sheet.
	Net Loss Per Share
	Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.  Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period.  Common share equivalents are only included when their effect is dilutive.  For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares outstanding due to the Company’s net loss position.
	The following table sets forth the computation of basic and diluted earnings per share:
			Three Months Ended March 31,
			2015			2014
	Numerator:
	Net loss attributable to common shareholders		$	(7,180,441	)	$	(3,199,006	)
	Denominator for basic and diluted net loss per share:
	Weighted average shares - basic and diluted		21,817,710			18,902,782
	Net loss per share attributable to common stockholders - basic and diluted		$	(0.33	)	(0.17		)
	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:
			March 31,
			2015		2014
	Options to purchase Common Stock		5,875,138		4,423,638
	Warrants to purchase Common stock		5,993,952		6,233,483
	Series A Convertible Preferred Stock		63,125		63,125
			11,932,215		10,720,246
	Recent Accounting Pronouncements
	In April 2015, a new accounting standard was issued that amends the presentation for debt issuance costs. Upon adoption, such costs shall be presented on our consolidated balance sheets as a direct deduction from the carrying amount of the related debt liability and not as a deferred charge presented in Other assets on our consolidated balance sheets. This new standard will be effective for interim and annual periods beginning on January 1, 2016, and is required to be retrospectively adopted. Adoption of this new standard is not expected to have a material impact on our consolidated balance sheets or related disclosures.
	In August 2014, the FASB issued an amendment to the accounting guidance related to the evaluation of an entity to continue as a going concern. The amendment establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity’s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2016. The new guidance will not have an impact on the Company’s financial position, results of operations or cash flows.
	In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). The standard provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Measurements
Fair Value Measurements
	3.  Fair Value Measurements
	The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March 31, 2015 and December 31, 2014:
			Fair Value Measurements at
			March 31, 2015
			Quoted Prices		Significant		Significant		Total
			in Active		Other		Unobservable
			Markets for		Observable		Inputs
			Identical Assets		Inputs		(Level 3)
			and Liabilities		(Level 2)
			(Level 1)
	Assets:
	Money market fund (1)		$	43,979,103	$	—	$	—	$	—
	Total Assets		$	43,979,103	$	—	$	—	$	—
	Liabilities:
	Derivative liabilities related to warrants		$	—	$	—	$	4,952,749	$	4,952,749
	Total Liabilities		$	—	$	—	$	4,952,749	$	4,952,749
			Fair Value Measurements at
			December 31, 2014
			Quoted Prices		Significant		Significant		Total
			in Active		Other		Unobservable
			Markets for		Observable		Inputs
			Identical Assets		Inputs		(Level 3)
			and Liabilities		(Level 2)
			(Level 1)
	Assets:
	Money market fund (1)		$	27,123,587	$	—	$	—	$	27,123,587
	Total Assets		$	27,123,587	$	—	$	—	$	27,123,587
	Liabilities:
	Derivative liabilities related to warrants		—		$	—	$	3,006,021	$	3,006,021
	Total Liabilities		$	—	$	—	$	3,006,021	$	3,006,021
		-1		Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets.
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2015:
	Description		Balance at		Unrealized		Balance at
			December 31,		Loss		March 31,
			2014				2015
	Derivative liabilities related to Warrants		$	3,006,021	$	1,946,728	$	4,952,749
	The unrealized loss on the derivative liabilities is recorded as a change in fair value of derivative liabilities in the Company’s condensed consolidated statement of operations.  A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40.  At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property and Equipment
Property and Equipment
	4.Property and Equipment
	Property and equipment consist of the following:
		As of March 31,			As of December, 31
		2015			2014
	Furniture and office equipment	$	410,660		$	365,954
	Leasehold Improvements	39,401			39,401
	Laboratory equipment	1,132,157			968,901
		1,582,218			1,374,256
	Less—accumulated depreciation and amortization	(559,684		)	(533,869		)
	Property and equipment, net	1,022,534			$	840,387

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt
Debt
	5.Debt
	Equipment Line of Credit
	In June 2013, the Company entered into a Loan and Security Agreement (“Equipment Line of Credit”) with Silicon Valley Bank that provided for cash borrowings for equipment of up to $1.0 million, secured by the equipment financed.  Under the terms of the agreement, interest was the greater of 5% or 4.6% above the U.S. Treasury Note as of the date of each borrowing.  Interest only payments were due on borrowings through December 31, 2013, with both interest and principal payments commencing in January 2014.  Any equipment advances after December 31, 2013 were subject to principal and interest payments immediately over a 30 month period following the advance.  In June 2014, the equipment loan was paid in full, the Company had no further obligations thereunder, and the bank released its security interest in such assets.
	The Company recorded approximately $9,500 in interest expense related to the equipment line of credit during the three months ended March 31, 2014.
	Loan and Security Agreement
	In June 2014, the Company entered into a $15,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing. The interest rate on such loan is 7.07% per annum.  The Company will make interest only payments on the outstanding amount of the loan on a monthly basis through July 2015, after which equal monthly payments of principal and interest are due until the loan maturity date of July 1, 2018.  The loan is secured by a security interest in all of the Company’s assets except intellectual property, which is subject to a negative pledge. In connection with the loan, the lenders received a warrant to purchase an aggregate 85,470 shares of the Company’s common stock at an exercise price of $3.51 per share exercisable for ten years from the date of issuance.  The original value of the warrants, totaling $235,857, was recorded as debt discount and additional paid-in capital as the warrants were equity classified.
	At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount.  In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the amortized portion of the final fee of $1,050,000.
	The Company is also subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified subordinated debt.  In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts. The Company was in compliance with all covenants as of March 31, 2015.
	As of March 31, 2015, amounts due under the agreement include 3,064,734 in current liabilities and $12,011,645 in long-term liabilities.  The Company recorded $389,838 in interest expense related to the loan and security agreement during the three months ended March 31, 2015.
	Future minimum principal payments under the loan and security agreement are as follows:
	March 31,
	2015	$	3,064,734
	2016	4,875,802
	2017	5,231,914
	2018	1,827,550
	Total long-term obligations	$	15,000,000

Derivative_Financial_Instrumen

Derivative Financial Instruments - Warrants	3 Months Ended
	Mar. 31, 2015
Derivative Financial Instruments - Warrants
Derivative Financial Instruments - Warrants
	6.  Derivative Financial Instruments - Warrants
	Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity, Trovagene has determined that certain warrants issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital as they were issued with other equity instruments.  In accordance with ASC Topic 815-40, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s statement of operations.  The Company estimates the fair value of (i) certain of these warrants using the Black-Scholes option pricing model and (ii) estimates the fair value of the price protected units using the Binomial option pricing model in order to determine the associated derivative instrument liability and change in fair value described above.
	The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:
		Three Months Ended
		March 31,
		2015			2014
	Estimated fair value of Trovagene common stock	$	6.81		$	5.73
	Expected warrant term	3.75 years			4.75 years
	Risk-free interest rate	0.89		%	1.73		%
	Expected volatility	75.40		%	83.0		%
	Dividend yield	0		%	0		%
	Expected volatility is based on the volatility of a peer group of companies with attributes similar to Trovagene.  The warrants have a transferability provision and based on guidance provided in SAB 107 for instruments issued with such a provision, Trovagene used the full contractual term as the expected term of the warrants.  The risk free rate is based on the U.S.  Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.
	The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.  For the period ending December 31, 2013, the derivative financial instruments liability in the table below only represents the Black-Scholes calculation whereas the loss recognized in the Statement of Operations represents both the Black-Scholes and the binomial methodology.
	Date	Description		Warrants		Derivative
						Instrument
						Liability
	December 31, 2014	Balance of derivative financial instruments liability		1,013,961		$	3,006,021
		Change in fair value of warrants during the period recognized as a loss in the condensed consolidated statement of operations		—		1,946,728
	March 31, 2015	Balance of derivative financial instruments liability		1,013,961		$	4,952,749

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity
Stockholders' Equity
	7.  Stockholders’ Equity
	Common Stock
	On January 25, 2013, the Company filed a Form S-3 Registration Statement to offer and sell in one or more offerings, any combination of common stock, preferred stock, warrants, or units having an aggregate initial offering price not exceeding $150,000,000.  The preferred stock, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other Trovagene securities.  This form was declared effective on February 4, 2013.  In addition, in connection with the Form S-3, the Company entered into an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock through them.  As payment for its services, the Agent is entitled to a 3% commission on gross proceeds.
	During the three month period ended March 31, 2015, the Company issued a total of 5,391,497 shares of Common Stock. The Company received gross proceeds of approximately $23.0 million from the sale of 5,111,110 shares of its common stock through an underwritten public offering in February 2015.  In addition, the Company received gross proceeds of approximately $312,000 from the sale of 50,011 shares of its common stock under the agreement with the Agent.  In addition, 66,750 shares were issued upon exercise of options for a weighted average price of $3.54 and 163,626 shares were issued upon net exercise of 271,668 warrants at an exercise price of $3.00.
	Stock Options
	Stock-based compensation expense related to Trovagene options have been recognized in operating results as follow:
		Three Months
		Ended March 31,
		2015			2014
	Included in research and development expense	$	289,197		189,635
	Included in cost of revenue	26,706			—
	Included in selling and marketing expense	80,488			22,680
	Included in general and administrative expense	315,350			347,458
	Total stock-based compensation expense	$	711,741		$	559,773
	The unrecognized compensation cost related to non-vested stock options outstanding at March 31, 2015 and 2014, net of expected forfeitures, was $7,715,890 and $3,695,076, respectively, both to be recognized over a weighted-average remaining vesting period of approximately three years.  The weighted average remaining contractual term of outstanding options as of March 31, 2015 was approximately eight years.
	The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the following periods indicated:
		Three Months Ended
		March 31,
		2015		2014
	Risk-free interest rate	1.6 – 1.9	%	1.5 – 1.6	%
	Dividend yield	0	%	0	%
	Expected volatility	75	%	83	%
	Expected term (in years)	6 yrs		5 yrs
	A summary of stock option activity and of changes in stock options outstanding under the Trovagene Stock Option Plan is presented below:
		Total Options		Weighted Average			Intrinsic
				Exercise Price			Value
				Per Share
	Balance outstanding, December 31, 2014	4,913,472		$	4.66		2,808,083
	Granted	1,080,000		6.35
	Exercised	(66,750	)	3.54
	Cancelled / Forfeited	(31,250	)	6.08
	Expired	(20,334	)	11.93
	Balance outstanding, March 31, 2015	5,875,138		4.95			12,559,574
	Exercisable at March 31, 2015	2,497,571		4.69			6,659,481
	The Trovagene Inc. 2014 Equity Incentive Plan (the “2014 EIP”) authorizing up to 2,500,000 shares of common stock for issuance under the Plan was approved by the Board of Directors in June 2014 and approved by the Shareholders at the September 17, 2014 Annual Shareholders’ Meeting.  As of March 31, 2015 there are 297,832 shares available for issuance under the 2014 EIP.
	Warrants
	A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
		Total Warrants		Weighted Average			Weighted Average
				Exercise Price			Remaining Contractual
				Per Share			Term
	Balance outstanding, December 31, 2014	6,265,620		$	3.85		3.57
	Granted	—
	Exercised	(271,668	)	3
	Balance outstanding, March 31, 2015	5,993,952		3.89			3.31

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies.
Commitments and Contingencies
	8. Commitments and Contingencies
	Executive and Consulting Agreements
	The Company has longer-term contractual commitments with various consultants and employees, including the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”).  The executive agreements with the CEO and CFO provide for severance payments.
	Lease Agreement
	The Company leases approximately 13,000 square feet of office space at a monthly rental rate of approximately $30,000 for the remaining term of the lease through December 2017.
	Research and Development Agreements
	During 2012, the Company entered into research agreements with University of Texas MD Anderson Cancer Center (“MDACC”) to provide samples and evaluate methods used by the Company in identification of pancreatic cancer mutations, as well as to measure the degree of concordance between results of cell-free DNA mutations analysis from urine samples and tumor tissue.  During 2013, the agreements were amended to increase the scope of the agreements.  Under these agreements, the Company has committed to pay approximately $266,000 for the services performed by MDACC.  As of March 31, 2015, the Company has incurred and recorded approximately $283,000 of research and development expenses related to these agreements.
	In June 2013, the Company entered into a research agreement with Illumina, Inc. (“Illumina”) pursuant to which the parties will work together to evaluate the potential for integrating the Company’s transrenal technology for isolating, extracting and genetic analysis of nucleic acids from urine with Illumina’s genetic analysis sequencing technology (the “Research Plan”).  The parties have agreed that all results and reagents from the Research Plan will be shared between the parties.  The agreement will terminate upon the earlier of 30 days after completion of the research plan or the one year anniversary of the agreement unless extended by mutual written agreement.  In October 2014, the agreement was extended to June 2015.
	In August 2013, the Company entered into a clinical trial agreement with the University of Southern California (“USC”), pursuant to which USC will provide the principal investigator and conduct the clinical trial related to the genetic characterization of metastatic colorectal cancers.  Under the agreement, the Company may pay USC approximately $277,000 for services provided. Through March 31, 2015 the Company has incurred and recorded approximately $48,000 of research and development expense related to this agreement.
	In December 2013, the Company entered into a clinical trial agreement with US Oncology Research LLC (“USOR”), pursuant to which USOR will provide the principal investigator and conduct the clinical trial related to the examining the utility of transrenal quantitative KRAS testing in disease monitoring in patients with metastatic pancreatic cancer.  Under the agreement, the Company may pay USOR approximately $270,000 for services provided.  As of March 31, 2015 the Company has incurred and recorded approximately $44,000 of research and development expense related to this agreement.
	In May 2014, the Company entered into a Strategic Research Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University to conduct one or more research agreements to evaluate use of Trovagene’s precision cancer monitoring technology in the management of cancer patients.  Under the agreement, each party will be responsible for its own costs and obligations under each agreement.  As of March 31, 2015, no costs have been incurred related to this agreement.
	In June 2014, the Company entered into a Sponsored Research Agreement with Dana Farber Cancer Institute to conduct a clinical study to evaluate use of Trovagene’s precision cancer monitoring technology in the management of lung cancer patients. Under the agreement, Trovagene may pay the collaborator in the study approximately $42,000 for services provided.  As of March 31, 2015, costs of approximately $10,000 have been incurred related to this agreement.
	In June 2014, the Company entered into a Sponsored Research Agreement with Memorial Sloan Cancer Center to conduct a clinical study for the detection of oncogenic tumor mutations in the urine of lung cancer patients.  Under the agreement with Memorial Sloan Kettering, Trovagene may pay them approximately $146,000 for services provided.  As of March 31, 2015 the Company has incurred approximately $43,000 related to this agreement.
	In September 2014, under the strategic partnership the Company established in March 2014, the Company entered into a Sponsored Research Agreement with Catholic Health Initiatives Center for Translational Research to conduct clinical studies to evaluate use of Trovagene’s PCM technology in the management of cancer patients. Under the terms of the agreement, Trovagene may pay the collaborator up to approximately $151,000 for services provided.  As of March 31, 2015 the Company has incurred approximately $61,000 related to this agreement.
	In October 2014, the Company entered into a Research Agreement with Genomac International, Ltd., for two clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer. Pursuant to the Research Agreement, Genomac will conduct a research study of minimally invasive molecular monitoring of efficiency of targeted biological therapy in advanced non-small lung cancer.  The Company is committed to pay Genomac approximately $175,000 for services provided.  As of March 31, 2015, the Company had incurred and recorded approximately $90,000 of research and development expenses.
	In December 2014, the Company entered into a clinical collaboration with City of Hope to conduct studies to determine the clinical utility of detecting and monitoring EGFR mutations in lung cancer patients using the Company’s Precision Cancer Monitoring platform.  The Company is committed to pay the City of Hope approximately $114,000 for services provided.  As of March 31, 2015, the Company had incurred and recorded approximately $17,000 related to this agreement.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies
Use of Estimates
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
Revenue Recognition
	Revenue Recognition
	Revenue is recognized when persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.
	Milestone, Royalty and License Revenues
	The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners.   These agreements may involve multiple elements such as license fees, royalties and milestone payments.  Revenue is recognized when the criteria described above have been met as well as the following:
		·		Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured.
		·		Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured.
		·		Milestone payments are recognized when both the milestone is achieved and the related payment is received.
	Diagnostic Service Revenues
	Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, bill third-party payors for testing.
	Diagnostic services revenue is recognized when the criteria described above has been met as well as upon cash collection until the Company can reliably estimate the amount that will be ultimately collected for our LDTs, at which time the Company will recognize diagnostic services revenues on an accrual basis.
Derivative Financial Instruments-Warrants
	Derivative Financial Instruments—Warrants
	The Company has issued common stock warrants in connection with the execution of certain equity financings.  Such warrants are classified as derivative liabilities under the provisions of FASB ASC 815 Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period.  Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity.  Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.”
	The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of Trovagene’s common share price, remaining life of the warrant, and risk-free interest rates at each period end.  The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per ASC 820, Fair Value Measurements.  At March 31, 2015, and December 31, 2014, the fair value of these warrants was $4,952,749 and $3,006,021, respectively, and were included in the derivative financial instruments liability on the balance sheet.
Net Loss Per Share
	Net Loss Per Share
	Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.  Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period.  Common share equivalents are only included when their effect is dilutive.  For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares outstanding due to the Company’s net loss position.
	The following table sets forth the computation of basic and diluted earnings per share:
			Three Months Ended March 31,
			2015			2014
	Numerator:
	Net loss attributable to common shareholders		$	(7,180,441	)	$	(3,199,006	)
	Denominator for basic and diluted net loss per share:
	Weighted average shares - basic and diluted		21,817,710			18,902,782
	Net loss per share attributable to common stockholders - basic and diluted		$	(0.33	)	(0.17		)
	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:
			March 31,
			2015		2014
	Options to purchase Common Stock		5,875,138		4,423,638
	Warrants to purchase Common stock		5,993,952		6,233,483
	Series A Convertible Preferred Stock		63,125		63,125
			11,932,215		10,720,246
Recent Accounting Pronouncements
	Recent Accounting Pronouncements
	In April 2015, a new accounting standard was issued that amends the presentation for debt issuance costs. Upon adoption, such costs shall be presented on our consolidated balance sheets as a direct deduction from the carrying amount of the related debt liability and not as a deferred charge presented in Other assets on our consolidated balance sheets. This new standard will be effective for interim and annual periods beginning on January 1, 2016, and is required to be retrospectively adopted. Adoption of this new standard is not expected to have a material impact on our consolidated balance sheets or related disclosures.
	In August 2014, the FASB issued an amendment to the accounting guidance related to the evaluation of an entity to continue as a going concern. The amendment establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity’s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2016. The new guidance will not have an impact on the Company’s financial position, results of operations or cash flows.
	In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). The standard provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies
Schedule of computation of basic and diluted earnings per share		Three Months Ended March 31,
		2015			2014
	Numerator:
	Net loss attributable to common shareholders	$	(7,180,441	)	$	(3,199,006	)
	Denominator for basic and diluted net loss per share:
	Weighted average shares - basic and diluted	21,817,710			18,902,782
	Net loss per share attributable to common stockholders - basic and diluted	$	(0.33	)	(0.17		)
Schedule of antidilutive securities excluded from the calculation of diluted net loss per share
		March 31,
		2015		2014
	Options to purchase Common Stock	5,875,138		4,423,638
	Warrants to purchase Common stock	5,993,952		6,233,483
	Series A Convertible Preferred Stock	63,125		63,125
		11,932,215		10,720,246

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Measurements
Schedule of the Company's assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy
			Fair Value Measurements at
			March 31, 2015
			Quoted Prices		Significant		Significant		Total
			in Active		Other		Unobservable
			Markets for		Observable		Inputs
			Identical Assets		Inputs		(Level 3)
			and Liabilities		(Level 2)
			(Level 1)
	Assets:
	Money market fund (1)		$	43,979,103	$	—	$	—	$	—
	Total Assets		$	43,979,103	$	—	$	—	$	—
	Liabilities:
	Derivative liabilities related to warrants		$	—	$	—	$	4,952,749	$	4,952,749
	Total Liabilities		$	—	$	—	$	4,952,749	$	4,952,749
			Fair Value Measurements at
			December 31, 2014
			Quoted Prices		Significant		Significant		Total
			in Active		Other		Unobservable
			Markets for		Observable		Inputs
			Identical Assets		Inputs		(Level 3)
			and Liabilities		(Level 2)
			(Level 1)
	Assets:
	Money market fund (1)		$	27,123,587	$	—	$	—	$	27,123,587
	Total Assets		$	27,123,587	$	—	$	—	$	27,123,587
	Liabilities:
	Derivative liabilities related to warrants		—		$	—	$	3,006,021	$	3,006,021
	Total Liabilities		$	—	$	—	$	3,006,021	$	3,006,021
		-1		Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets.
Schedule of changes in the fair value of the Company's Level 3 liabilities
	Description		Balance at		Unrealized		Balance at
			December 31,		Loss		March 31,
			2014				2015
	Derivative liabilities related to Warrants		$	3,006,021	$	1,946,728	$	4,952,749

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property and Equipment
Schedule of components of property and equipment		As of March 31,			As of December, 31
		2015			2014
	Furniture and office equipment	$	410,660		$	365,954
	Leasehold Improvements	39,401			39,401
	Laboratory equipment	1,132,157			968,901
		1,582,218			1,374,256
	Less—accumulated depreciation and amortization	(559,684		)	(533,869		)
	Property and equipment, net	1,022,534			$	840,387

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Debt
Schedule of future minimum principal payments under loan and security agreement
	March 31,
	2015	$	3,064,734
	2016	4,875,802
	2017	5,231,914
	2018	1,827,550
	Total long-term obligations	$	15,000,000

Derivative_Financial_Instrumen1

Derivative Financial Instruments - Warrants (Tables) (Black Scholes Option Pricing Method)	3 Months Ended
	Mar. 31, 2015
Black Scholes Option Pricing Method
Derivative financial instruments
Schedule of assumptions used to determine the fair value of the warrants
		Three Months Ended
		March 31,
		2015			2014
	Estimated fair value of Trovagene common stock	$	6.81		$	5.73
	Expected warrant term	3.75 years			4.75 years
	Risk-free interest rate	0.89		%	1.73		%
	Expected volatility	75.40		%	83.0		%
	Dividend yield	0		%	0		%
Schedule of components of changes in the Company's derivative financial instruments liability balance
	Date	Description		Warrants		Derivative
						Instrument
						Liability
	December 31, 2014	Balance of derivative financial instruments liability		1,013,961		$	3,006,021
		Change in fair value of warrants during the period recognized as a loss in the condensed consolidated statement of operations		—		1,946,728
	March 31, 2015	Balance of derivative financial instruments liability		1,013,961		$	4,952,749

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity
Schedule of stock-based compensation expense
		Three Months
		Ended March 31,
		2015			2014
	Included in research and development expense	$	289,197		189,635
	Included in cost of revenue	26,706			—
	Included in selling and marketing expense	80,488			22,680
	Included in general and administrative expense	315,350			347,458
	Total stock-based compensation expense	$	711,741		$	559,773
Schedule of assumptions to estimate fair value of stock option awards
		Three Months Ended
		March 31,
		2015		2014
	Risk-free interest rate	1.6 – 1.9	%	1.5 – 1.6	%
	Dividend yield	0	%	0	%
	Expected volatility	75	%	83	%
	Expected term (in years)	6 yrs		5 yrs
Summary of stock option activity and of changes in stock options outstanding		Total Options		Weighted Average			Intrinsic
				Exercise Price			Value
				Per Share
	Balance outstanding, December 31, 2014	4,913,472		$	4.66		2,808,083
	Granted	1,080,000		6.35
	Exercised	(66,750	)	3.54
	Cancelled / Forfeited	(31,250	)	6.08
	Expired	(20,334	)	11.93
	Balance outstanding, March 31, 2015	5,875,138		4.95			12,559,574
	Exercisable at March 31, 2015	2,497,571		4.69			6,659,481
Summary of warrant activity and changes in warrants outstanding		Total Warrants		Weighted Average			Weighted Average
				Exercise Price			Remaining Contractual
				Per Share			Term
	Balance outstanding, December 31, 2014	6,265,620		$	3.85		3.57
	Granted	—
	Exercised	(271,668	)	3
	Balance outstanding, March 31, 2015	5,993,952		3.89			3.31

Basis_of_Presentation_and_Summ

Basis of Presentation and Summary of Significant Accounting Policies (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Derivative financial instruments
Derivative liabilities related to warrants	$4,952,749	$3,006,021
Warrants | Black Scholes Option Pricing Method
Derivative financial instruments
Derivative liabilities related to warrants	$4,952,749	$3,006,021

Basis_of_Presentation_and_Summ1

Basis of Presentation and Summary of Significant Accounting Policies (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Numerator
Net loss	($7,180,441)	($3,199,006)
Denominator
Weighted average shares outstanding - basic	21,817,710	18,902,782
Weighted average shares used to compute diluted net loss	21,817,710	18,902,782
Net loss per share diluted	($0.33)	($0.17)

Basis_of_Presentation_and_Summ2

Basis of Presentation and Summary of Significant Accounting Policies (Details 3)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Net Loss Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,932,215	10,720,246
Stock options
Net Loss Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,875,138	4,423,638
Warrants
Net Loss Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,993,952	6,233,483
Series A Convertible Preferred Stock
Net Loss Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	63,125	63,125

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Liabilities:
Derivative liabilities related to warrants	$4,952,749	$3,006,021
Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Money market fund	43,979,103	27,123,587
Total Assets	43,979,103	27,123,587
Recurring basis | Significant Unobservable Inputs (Level 3)
Liabilities:
Derivative liabilities related to warrants	4,952,749	3,006,021
Total Liabilities	4,952,749	3,006,021
Recurring basis | Total
Assets:
Money market fund		27,123,587
Total Assets		27,123,587
Liabilities:
Derivative liabilities related to warrants	4,952,749	3,006,021
Total Liabilities	$4,952,749	$3,006,021

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (Warrants, USD $)	3 Months Ended
	Mar. 31, 2015
Warrants
Reconciliation of the beginning and ending balances
Balance at the beginning of the period	$3,006,021
Unrealized gain	1,946,728
Balance at the end of the period	$4,952,749

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, equipment and depreciation and amortization
Property and equipment, gross	$1,582,218	$1,374,256
Less-accumulated depreciation and amortization	-559,684	-533,869
Property, Plant and Equipment, Net, Total	1,022,534	840,387
Furniture and office equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	410,660	365,954
Leasehold Improvements
Property, equipment and depreciation and amortization
Property and equipment, gross	39,401	39,401
Laboratory equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	$1,132,157	$968,901

Debt_Details

Debt (Details) (USD $)	1 Months Ended	3 Months Ended
	Jun. 30, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jun. 30, 2013
	item
Debt
Amount borrowed included in current liabilities		$3,064,734		$1,898,548
Amount borrowed, long-term liabilities		12,011,645		13,053,117
Secured Debt
Debt
Interest expenses recorded		389,838
Face value of term loan		15,000,000
Number of banks, with which agreement is entered	2
Interest rate (as a percent)	7.07%
Number of common shares that can be purchased upon exercise of warrant	85,470
Exercise price of warrants (in dollars per share)	3.51
Exercisable term	10 years
Value of warrants recorded as debt discount and additional paid in capital	235,857
Amortized portion of final fee upon repayment		1,050,000
Future minimum principal payments
2015		3,064,734
2016		4,875,802
2017		5,231,914
2018		1,827,550
Total long-term obligations		15,000,000
Secured Debt | Minimum
Debt
Pre-payment fees (as a percent)		1.00%
Secured Debt | Maximum
Debt
Pre-payment fees (as a percent)		3.00%
Loan and Security Agreement
Debt
Maximum borrowing capacity of credit facility					1,000,000
Fixed interest rate to determine variable interest (as a percent)		5.00%
Variable spread over U.S. Treasury Note rate of interest (as a percent)		4.60%
Period for payment of principal and interest after date of advances		30 months
Interest expenses recorded			$9,500

Derivative_Financial_Instrumen2

Derivative Financial Instruments - Warrants (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)	6,265,620
Balance of warrants outstanding at the end of the period (in shares)	5,993,952
Balance of derivative financial instruments liability at the beginning of the period	$3,006,021
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	1,946,728	-32,846
Balance of derivative financial instruments liability at the end of the period	4,952,749
Warrants | Black Scholes Option Pricing Method
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share)	$6.81	$5.73
Expected warrant term	3 years 9 months	4 months 23 days
Risk-free interest rate (as a percent)	0.89%	1.73%
Expected volatility (as a percent)	75.40%	83.00%
Dividend yield (as a percent)	0.00%	0.00%
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)	1,013,961
Balance of warrants outstanding at the end of the period (in shares)	1,013,961
Balance of derivative financial instruments liability at the beginning of the period	3,006,021
Balance of derivative financial instruments liability at the end of the period	$4,952,749

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended	0 Months Ended
	Mar. 31, 2015	Jan. 25, 2013
Proceeds of sale of common stock, net of expenses	$21,445,785
Warrants exercised (in shares)	271,668
Exercise price of warrants exercised (in dollars per share)	$3
Warrant exercise price of $3.00 per share
Warrants exercised (in shares)	271,668
Exercise price of warrants (in dollars per share)	3
Common Stock
Shares of common stock issued	5,391,497
Common Stock | Option exercise price, weighted average of $3.54 per share
Shares issued upon exercise of options	66,750
Exercise price of stock options exercised (in dollars per share)	$3.54
Common Stock | Warrant exercise price of $3.00 per share
Issuance of common stock upon net exercise of warrant (in shares)	163,626
Public Offering and Controlled Equity Offering | Underwritten Public Offering 2015 | Common Stock
Shares of common stock issued	5,111,110
Proceeds of sale of common stock, net of expenses	23,000,000
Agent | Public Offering and Controlled Equity Offering
Commission as percentage of gross proceeds		3.00%
Agent | Public Offering and Controlled Equity Offering | Underwritten Public Offering 2015 | Common Stock
Shares of common stock issued	50,011
Proceeds of sale of common stock, net of expenses	312,000
Maximum | Public Offering and Controlled Equity Offering
Aggregate initial offering price		150,000,000
Maximum | Agent | Public Offering and Controlled Equity Offering
Aggregate initial offering price		30,000,000

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock-based compensation expense
Total stock based compensation expense	$711,741	$559,773
Research and Development Expense
Stock-based compensation expense
Total stock based compensation expense	289,197	189,635
Cost of Revenue
Stock-based compensation expense
Total stock based compensation expense	26,706
Selling and Marketing Expense.
Stock-based compensation expense
Total stock based compensation expense	80,488	22,680
General and Administrative Expense.
Stock-based compensation expense
Total stock based compensation expense	$315,350	$347,458

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Sep. 17, 2014
Stock options
Weighted-average assumptions
Dividend yield (as a percent)	0.00%	0.00%
Expected volatility (as a percent)	75.00%	83.00%
Expected term	6 years	5 years
Unrecognized compensation cost
Unrecognized compensation cost	$7,715,890	$3,695,076
Weighted-average remaining vesting period for recognition	3 years
Number of Options
Balance outstanding at the beginning of the period (in shares)	4,913,472
Granted (in shares)	1,080,000
Exercised (in shares)	-66,750
Cancelled / Forfeited (in shares)	-31,250
Expired (in shares)	-20,334
Balance outstanding at the end of the period (in shares)	5,875,138
Vested and exercisable at the end of the period (in shares)	2,497,571
Weighted Average Exercise Price Per Share
Balance outstanding at the beginning of the period (in dollars per share)	$4.66
Granted (in dollars per share)	$6.35
Exercised (in dollars per share)	$3.54
Canceled / Forfeited (in dollars per share)	$6.08
Expired (in dollars per share)	$11.93
Balance outstanding at the end of the period (in dollars per share)	$4.95
Vested and exercisable at the end of the period (in dollars per share)	$4.69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Options Outstanding, Intrinsic Value	12,559,574		2,808,083
Vested and Exercisable at the end of the period, Intrinsic Value	$6,659,481
Options Outstanding, Weighted Average Contractual Life	8 years
Stock options | Minimum
Weighted-average assumptions
Risk-free interest rate (as a percent)	1.60%	1.50%
Stock options | Maximum
Weighted-average assumptions
Risk-free interest rate (as a percent)	1.90%	1.60%
2014 EIP
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Authorized shares under the plan				2,500,000
Number of remaining shares available for issuance	297,832

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Number of Warrants
Balance of warrants outstanding at the beginning of the period (in shares)	6,265,620
Exercised (in shares)	-271,668
Balance of warrants outstanding at the end of the period (in shares)	5,993,952	6,265,620
Weighted Average Exercise Price Per Share
Weighted average exercise price of warrants at the beginning of the period (in dollars per share)	$3.85
Exercised (in dollars per share)	$3
Weighted average exercise price of warrants at the end of the period (in dollars per share)	$3.89	$3.85
Term
Balance of warrants outstanding at the beginning of the period	3 years 3 months 22 days	3 years 6 months 26 days
Balance of warrants outstanding at the end of the period	3 years 3 months 22 days	3 years 6 months 26 days

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Lease Agreements
Area under lease (in square feet)	13,000
Minimum
Lease Agreements
Monthly rental rate	$30,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details 2) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2013	Dec. 31, 2013	31-May-14	Dec. 31, 2014	Jun. 30, 2014	Sep. 30, 2014	Oct. 14, 2014
					item
Commitments and contingencies
Research and development expense	$2,197,659	$1,442,521
License and Services Revenue	2,166
Research and Development Agreements | MDACC
Commitments and contingencies
Amount committed to be paid				266,000
Research and development expense	283,000
Research and Development Agreements | Illumina
Commitments and contingencies
Period of termination of agreement, after completion of the research plan			30 days
Period of termination of agreement, on its anniversary unless extended by mutual written agreement			1 year
Research and Development Agreements | USC
Commitments and contingencies
Amount committed to be paid	232,000
Research and development expense	48,000
Research and Development Agreements | USOR
Commitments and contingencies
Amount committed to be paid	270,000
Research and development expense	44,000
Research and Development Agreements | Robert H Lurie Comprehensive Cancer Center
Commitments and contingencies
Research and development expense	0
Research and Development Agreements | Robert H Lurie Comprehensive Cancer Center | Minimum
Commitments and contingencies
Number of research agreements					1
Research and Development Agreements | City of Hope
Commitments and contingencies
Amount committed to be paid						114,000
Research and development expense	17,000
Sponsored Research Agreement | Dana Farber Cancer Institute
Commitments and contingencies
Amount committed to be paid							42,000
Research and development expense	10,000
Sponsored Research Agreement | Memorial Sloan Cancer Center
Commitments and contingencies
Amount committed to be paid							146,000
Research and development expense	43,000
Sponsored Research Agreement | Catholic Health Initiatives Center for Translational Research
Commitments and contingencies
Research and development expense	61,000
Sponsored Research Agreement | Catholic Health Initiatives Center for Translational Research | Maximum
Commitments and contingencies
Amount committed to be paid								151,000
Sponsored Research Agreement | Genomac International, Ltd
Commitments and contingencies
Amount committed to be paid									175,000
Research and development expense	$90,000